leadf
logo-loader
viewEmyria Ltd

Emyria's Michael Winlo details new global partnership with UK-based Sapphire Medical Clinics

Emyria Ltd’s (ASX:EMD) Dr Michael Winlo caught up with Proactive's Andrew Scott after reporting that its clinical operations subsidiary, Emerald Clinics, has entered into a global partnership with UK-based Sapphire Medical Clinics. The partnership will provide a new source of data to bolster Emyria’s growing cannabinoid data platform and allow Emyria to leverage Sapphire’s resources and infrastructure in the UK to provide services to UK patients.

Quick facts: Emyria Ltd

Price: 0.077 AUD

ASX:EMD
Market: ASX
Market Cap: $16.28 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Emyria Ltd named herein, including the promotion by the Company of Emyria Ltd in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Zelira Therapeutics and Emyria team up for 'disruptive' autism spectrum...

Zelira Therapeutics Ltd's (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) Richard Hopkins and Emyria Ltd's (ASX:EMD) Michael Winlo speak to Proactive's Andrew Scott after announcing they've entered into an agreement to conduct an observational trial for patients diagnosed with autism spectrum disorder (ASD)...

2 weeks, 4 days ago

2 min read